<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371213">
  <stage>Registered</stage>
  <submitdate>10/10/2016</submitdate>
  <approvaldate>16/11/2016</approvaldate>
  <actrnumber>ACTRN12616001581459</actrnumber>
  <trial_identification>
    <studytitle>Longitudinal study of early Alzheimer's disease using genetics, brain imaging and behavioural assessments.</studytitle>
    <scientifictitle>Prospective Imaging Study of Ageing:  Genes, Brain and Behaviour</scientifictitle>
    <utrn>NIL</utrn>
    <trialacronym>PISA</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>dementia</healthcondition>
    <healthcondition>Mild cognitive impairment</healthcondition>
    <healthcondition>Alzheimer's disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions> There will be 2 exposure groups in this study:
Group 1: Patients with Alzheimers disease
Group 2: Patients with amnestic mild cognitive impairment

Participants will complete a PET Imaging exam, MRI exam, neuropsychological assessment and provide a blood sample twice within a 5-year period, with a 2-year interval between each set of tests. Participants will also be asked to wear a smart sensing device periodically over the 5-year study period.Smart sensing wrist device which  will record movement profile and heart rate. Participants are asked to wear the device for a minimum of 5days of each month, for the duration of the study. </interventions>
    <comparator>Healthy controls will complete a PET Imaging exam, MRI exam, neuropsychological assessment and provide a blood sample twice within a 5-year period, with a 2-year interval between each set of tests. Participants will also be asked to wear a smart sensing watch periodically for the 5-year study period.</comparator>
    <control>Active</control>
    <interventioncode>Early Detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To measure beta-amyloid accumulation in the brain via PET Imaging. Standardized uptake values (SUV) will be calculated for all brain regions examined and SUV ratios (SUVR) will be generated by dividing all regional SUV by the cerebellar cortex SUV. Region of interest measurements will be averaged across both hemispheres. Neocortical amyloid burden will be expressed as the average SUVR of the area-weighted mean of frontal, superior parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate regions. PET data will be corrected for partial volume effects using a 3 compartment model.

</outcome>
      <timepoint>Participants will undergo 2 PET Imaging Exams with a 2 year interval between each exam. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Measuring biological changes in the brain structure and function via MRI scan. 

</outcome>
      <timepoint>Two MRI scans with a 2 year interval between each scan</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Routine biochemistry -biochemistry measurements taken:
Urea
Creatinine
Electrolytes
Liver function tests
Cholesterol
Riglycerides
Glucose
CRP
</outcome>
      <timepoint>2 blood sample collections with a 2 year interval between each collection</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Comprehensive neuropsychological testing using validated measures to assess memory and cognition:
1.	Wechsler Abbreviated Scale of Intelligence  II 
2.	Rey Auditory Verbal Learning Test
3.	Rey Complex Figure Test
4.	National Adult Reading Test -2nd Edition
5.	Trail making Test
6.	Stroop Test
This is a composite secondary outcome.                                                                                            
</outcome>
      <timepoint>Baseline and follow-up neuropsych assessments with a 2 year interval between each assessment. 

</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluating participants' lifestyle factors via smart sensing devices. 
Smart sensing wrist device which  will record movement profile and heart rate. Participants are asked to wear the device for a minimum of 5days of each month, for the duration of the study.  Movement profile and heart rate combined analyses to assess lifestyle factors. This is a composite secondary outcome. </outcome>
      <timepoint>Participants are asked to wear the device periodically over 5 years. 
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SNP analysis</outcome>
      <timepoint>2 blood sample collections with a 2 year interval between each collection</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Overall Study:
aged between the ages of 40 and 80
fluent in English
clinical diagnosis of Alzheimers disease (Group 1) 
OR
meet a research consensus classification of amnestic MCI (Group 2)
OR
No current or past history of neurological conditions and consented to participate in GWAS studies at QIMR Berghofer (with existing GWAS information + consent to participate in other HREC approved studies).
Completed an MRI exam

Neuropsychological testing and Blood sample collection: 
Participants who have met the overall study inclusion criteria will be recruited into these components of the study.

MRI Imaging
overall study inclusion criteria 
MRI clearance
All participants who have been granted MRI clearance outlined in the Metals Safety Questionnaire, and have met the inclusion criteria for the Overall study will be included in this component.  

PET Imaging: 
Participants who have completed the MRI exam and have met the inclusion criteria for the overall study may be recruited into this component of the study. 

Smart Sensing Study: 
All participants who own a smart phone, have completed all other testing components and have met the inclusion criteria for the overall study may be recruited into this component of the study. 

</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Overall study: 
*Inability to provide formal consent
*Any significant neurological disease (other than Alzheimer's disease) or history of significant head trauma followed by persistent neurological deficits or known structural brain abnormalities
*Longstanding (&gt;10 years) history of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed
*History of major depression, bipolar disorder or schizophrenia that puts assessment of cognitive impairment into question
*Any significant disease or unstable medical condition that could affect neuropsychological testing (i.e., chronic renal failure, chronic hepatic disease, severe pulmonary disease)
*History of brain injury with significant sequelae (i.e. haemorrhage, oedema, hypoxia) or invasive neurosurgery. 

Neuropsychological testing and Blood sample collection: 
Participants who have not met any of the exclusion criteria outlined in the Overall Study will be recruited into these components of the study.  
Excluded from MRI imaging 
*presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, metallic fragments near the eyes or spinal cord, or cochlear implant.  (Dental fillings do not present a risk for MRI). 

Excluded from PET Imaging: 
*Those who are pregnant or breastfeeding
*extensive white matter lesions or other neurological conditions are detected at MRI
*Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body, metallic fragments near the eyes or spinal cord, or cochlear implant.  (Dental fillings do not present a risk for MRI). 
*History of hypersensitivity reaction to Flutemetamol F18, or any other inactive ingredient in Flutemetamol F18 
Smart Sensing Study:
*Participants who do not own a smartphone will not be invited to complete this component of the study.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Case control</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>21/11/2016</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate>1/11/2018</anticipatedenddate>
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>QIMR Berghofer Medical Research Institute</primarysponsorname>
    <primarysponsoraddress>300 Herston Rd, Herston QLD 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>GPO Box 1421 Canberra ACT 2601 </fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The PISA project seeks to reduce Australias future dementia burden by elucidating methods to identify those Australians at the very early stages of dementia.  This project aims to achieve this goal by monitoring participants physical, cognitive and neurobiological ageing in a cross-sectional, longitudinal design. The tests used in this study include cognitive testing, MRI examinations, PET imaging examinations and blood sample collection. Participants will undergo testing once every two years, over a five year period. Participants will also be given a wearable smart sensing device that will record personalised health data in day to day life, over the course of the study.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>QIMR Berghofer Human REsearch Ethics Committee</ethicname>
      <ethicaddress>300 Herston Rd, Herston QLD 4006</ethicaddress>
      <ethicapprovaldate />
      <hrec>P2193</hrec>
      <ethicsubmitdate>26/07/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Brisbane &amp; Womenâ€™s Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>HREC Office, Level 7, Block 7 RBWH
RGO Office, Level 4, UQCCR, RBWH
Butterfield Street, Herston Qld 4029</ethicaddress>
      <ethicapprovaldate>4/05/2016</ethicapprovaldate>
      <hrec>HREC/16/QRBW/104</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Christine Guo</name>
      <address>QIMR Berghofer Medical Research Institute
300 Herston Road, Herston 4006 QLD
</address>
      <phone>+61 7 3362 0111 </phone>
      <fax />
      <email>Christine.Guo@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Taria Tane</name>
      <address>QIMR Berghofer Medical Research Institute
300 Herston Road, Herston 4006 QLD
</address>
      <phone>+61 7 3362 0111 </phone>
      <fax />
      <email>Taria.Tane@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Michael Breakspear</name>
      <address>QIMR Berghofer Medical Research Institute
300 Herston Road, Herston 4006 QLD
</address>
      <phone>+61 7 3362 0111 </phone>
      <fax />
      <email>Michael.Breakspear@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Sashika Naidoo</name>
      <address>QIMR Berghofer Medical Research Institute
300 Herston Rd, Herston QLD 4006</address>
      <phone>	+61 7 3362 0433</phone>
      <fax />
      <email>Sashika.Naidoo@qimrberghofer.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>